Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 27, 2025 06:00 ET
|
Verona Pharma plc
OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers...
Verona Pharma Announces March 2025 Investor Conference Participation
February 18, 2025 06:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at...
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
February 13, 2025 06:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth...